GW&K Investment Management LLC Trims Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

GW&K Investment Management LLC reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,745,641 shares of the biopharmaceutical company's stock after selling 16,620 shares during the quarter. Halozyme Therapeutics accounts for approximately 0.7% of GW&K Investment Management LLC's portfolio, making the stock its 27th largest holding. GW&K Investment Management LLC owned about 1.37% of Halozyme Therapeutics worth $83,459,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Louisiana State Employees Retirement System increased its position in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock valued at $1,688,000 after acquiring an additional 200 shares during the period. Verdence Capital Advisors LLC increased its holdings in Halozyme Therapeutics by 1.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company's stock valued at $757,000 after purchasing an additional 252 shares during the period. State of New Jersey Common Pension Fund D raised its position in Halozyme Therapeutics by 0.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock valued at $2,279,000 after purchasing an additional 302 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the period. Finally, Nations Financial Group Inc. IA ADV lifted its holdings in Halozyme Therapeutics by 2.4% in the 4th quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company's stock worth $672,000 after buying an additional 328 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Remove Ads

Halozyme Therapeutics Stock Up 0.3 %

Halozyme Therapeutics stock traded up $0.18 during mid-day trading on Tuesday, reaching $58.14. The stock had a trading volume of 1,478,536 shares, compared to its average volume of 1,289,172. The company has a market capitalization of $7.16 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $65.53. The company has a 50-day moving average price of $54.74 and a two-hundred day moving average price of $54.72.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HALO. HC Wainwright boosted their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Wells Fargo & Company cut their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Finally, Benchmark reissued a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $62.78.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock valued at $1,754,451 over the last ninety days. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.